Form 4: Beam Therapeutics CEO John M. Evans Acquires 77,500 Shares of Common Stock

CEO John M. Evans acquired 77,500 shares of Beam Therapeutics common stock on March 31, 2025, and holds over 1 million shares directly and another 103,000 indirectly.

Summary

• On March 31, 2025, John M. Evans, CEO of Beam Therapeutics Inc., acquired 77,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Evans directly owns 1,016,159 shares of Beam Therapeutics common stock.
• Evans also indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• The 77,500 shares were granted as restricted stock units (RSUs) under the company's 2019 Equity Incentive Plan.
• The RSUs vest in four equal installments on the anniversaries of the grant date, contingent upon Evans' continued service with Beam Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by the CEO, which is part of their compensation package. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Positives

• The acquisition of shares by the CEO could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service with BEAM through each vesting date.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Stakeholder Impact

• The acquisition of shares by the CEO could positively influence shareholder confidence.

Key Dates

Keywords

Beam Therapeutics, John M. Evans, CEO, Form 4, Stock Acquisition, Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership